Showing records 1 to 4 of 4 :

[Search Summary]

Title Pub. Date Int. Class Applicant

1. (WO 2006/042362) USE OF

4-(4-METHYLPIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-(PYRIDIN-3-YL)PYRIMIDIN-2-

YLAMINO)PHENYL]-BENZAMIDE

TO INHIBIT THE TYROSINE KINASE RECEPTOR C-FMS 27.04.2006 A61K 31/506 MEDVET SCIENCE PTY LTD

This invention relates to the use of 4-(4-methylpiperazin-l-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-

ylamino)phenyl]-benzamide, (also known as imatinib, gleevec, glivec, cgp57148b or 8TI571), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of c-fms associated diseases including; choriocarcinoma, malignant histiocytosis, embryonal carcinoma, endometrial carcinoma, brain microglial tumours, sarcoidosis, microglial cell involvement in normal and variant Creutzfeld- Jacob disease, and amyotrophic lateral sclerosis.

--------------------------------------------------------------------------------

2. (WO 2004/035822) METHODS TO PREDICT EDEMA AS A SIDE EFFECT OF DRUG TREATMENT 29.04.2004 C12Q 1/68 NOVARTIS AG

This invention provides methods to predict the likelihood of occurrence of the side effect of edema in patients treated with a drug including, but not limited to, a TKI, such as Imatinib or GLEEVEC™/GLIVEC®. The methods employed use gene expression profile comparisons and the determination of specific SNPs and in the IL-1â gene. Methods of treatment of edema and kits for the performance of the above assays are also provided.

--------------------------------------------------------------------------------

3. (WO 2004/032925) USE OF IMATINIB (GLIVEC, STI-571) TO INHIBIT BREAST CANCER RESISTANCE PROTEIN (BCRP)-MEDIATED RESISTANCE TO THERAPEUTIC AGENTS 22.04.2004 A61K 31/137 NOVARTIS AG

The present invention relates to the use of imatinib of the following formula (I) or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a cancer that expresses breast cancer resistant protein (BCRP) in a human subject in need of such a treatment.

--------------------------------------------------------------------------------

4. (WO 2003/084543) COMBINATION OF GLIVEC(STI571) WITH A CYCLIN-DEPENDENT KINASE INHIBITOR, ESPECIALLY FLAVOPIRIDOL IN THE TREATMENT OF CANCER

16.10.2003 A61K 31/445 VIRGINIA COMMONWEALTH UNIVERSITY

The present invention pertains to a combination for simultaneous, separate or sequential use which comprises (a) a cyclin-dependent kinase inhibitor and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide and to its use for the treatment of cancer, especially of Bcr/Abl+ leukemia resistant to compound of formula (I).